HC Wainwright Reiterates “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM)

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $4.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 197.40% from the stock’s previous close.

Separately, StockNews.com upgraded Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, April 18th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Actinium Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $7.40.

Actinium Pharmaceuticals Stock Performance

Shares of ATNM traded up $0.04 during trading hours on Monday, reaching $1.35. The stock had a trading volume of 337,452 shares, compared to its average volume of 502,801. The company’s 50-day moving average is $1.29 and its two-hundred day moving average is $1.37. Actinium Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $10.24. The stock has a market capitalization of $41.96 million, a PE ratio of -0.97 and a beta of -0.27.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ATNM. Geode Capital Management LLC lifted its position in Actinium Pharmaceuticals by 3.0% during the third quarter. Geode Capital Management LLC now owns 686,153 shares of the company’s stock valued at $1,290,000 after buying an additional 19,843 shares during the period. Northern Trust Corp lifted its position in Actinium Pharmaceuticals by 4.9% during the 4th quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock valued at $317,000 after acquiring an additional 11,812 shares during the period. Los Angeles Capital Management LLC boosted its stake in Actinium Pharmaceuticals by 25.0% during the fourth quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock worth $270,000 after acquiring an additional 42,770 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Actinium Pharmaceuticals by 49.9% in the fourth quarter. Renaissance Technologies LLC now owns 190,400 shares of the company’s stock worth $240,000 after purchasing an additional 63,400 shares during the period. Finally, Squarepoint Ops LLC grew its stake in shares of Actinium Pharmaceuticals by 25.4% in the 4th quarter. Squarepoint Ops LLC now owns 183,262 shares of the company’s stock worth $231,000 after buying an additional 37,159 shares during the last quarter. 27.50% of the stock is owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).